CRISPR Therapeutics Financials - Benzinga

CRISPR Therapeutics AG

CRSPNASDAQ

Trade with Public

Trade with Public

$56.45

0.450.81%

最終更新: Sep 30, 2:41 PM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

CRISPR Therapeutics Financials

CRISPR Therapeutics (CRSP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.17) by 19.66 percent. This is a 60.83 percent increase over losses of $(2.40) per share

Benzinga Newsdesk

PRO
CRISPR Therapeutics Q1 EPS $(1.28) Misses $(1.20) Estimate, Sales $1.458M Miss $2.700M Estimate

Benzinga Newsdesk

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pipeline also advancing with promising data.

Vandana Singh

CRISPR Therapeutics Earnings Report: Q4 Overview

Benzinga Insights

PRO
CRISPR Therapeutics Q4 EPS $(1.37) Misses $(1.09) Estimate, Sales $864.000K

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.09) by 25.92 percent. This is a 211.36 percent decrease over losses of $(0.44) per share

Benzinga Newsdesk

PRO
CRISPR Therapeutics Q3 EPS $(1.17) Beats $(1.24) Estimate, Sales $889.000K Miss $8.904M Estimate

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.24) by 5.26 percent. This is a 15.84 percent decrease over losses of $(1.01) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved